US5785642A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for treating urinary incontinence in mammals
Assignee: Micro Therapeutics Inc
•
Filing: 1996-10-18
•
Granted: 1998-07-28
•
Expires: 2016-10-18
Abstract
Abstract Disclosed are methods for treating urinary incontinence in a mammal wherein a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent is delivered to the periurethral tissue of the mammal.
Inventors
- 👤 George Wallace
- 👤 Richard J. Greff
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 10:22
CPC Classifications
A; A61; A61L; A61L31/00; A61L31/04; A61L31/042; A61L24/00; A61L24/04; A61L24/06; A61L24/08; A61L27/00; A61L27/14; A61L27/16; A61L27/20; A61L31/048; A61P; A61P13/00; A61P13/02; A61F; A61F2/00; A61F2/0004; A61F2/0031; A61F2/0036; A61L2430/00; A61L2430/36
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
77 words
A method for treating urinary incontinence in a mammal, which method comprises delivering a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent to the periurethral tissue of the mammal wherein said biocompatible polymer has an equilibrium water content of less than about 15% water and further wherein said delivery is conducted under conditions such that a coherent polymeric mass forms in situ in the periurethral tissue thereby reducing urinary incontinence in the mammal.
Claim 2
Independent Claim
77 words
A method for treating urinary incontinence in a mammal, which method comprises delivering a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent to the periurethral tissue of the mammal wherein said biocompatible polymer has an equilibrium water content of less than about 15% water and further wherein said delivery is conducted under conditions such that a coherent polymeric mass forms in situ in the periurethral tissue thereby reducing urinary incontinence in the mammal.
Claim 3
Dependent Claim
26 words
The method according to claim 1 wherein said biocompatible polymer is selected from the group consisting of cellulose acetate polymers, ethylene vinyl alcohol copolymers and polyacrylates.
Claim 4
Dependent Claim
21 words
The method according to claim 2 wherein said biocompatible polymer is a cellulose acetate polymer or an ethylene vinyl alcohol copolymer.
Claim 5
Dependent Claim
21 words
The method according to claim 1 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol, and acetone.
Claim 6
Dependent Claim
12 words
The method according to claim 4 wherein said biocompatible solvent is dimethylsulfoxide.
Claim 7
Dependent Claim
16 words
The method according to claim 1 wherein said contrast agent is a water insoluble contrast agent.
Claim 8
Dependent Claim
26 words
The method according to claim 6 wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum oxide, tungsten, and barium sulfate.
Claim 9
Dependent Claim
16 words
The method according to claim 1 wherein said contrast agent is a water soluble contrast agent.
Claim 10
Dependent Claim
14 words
The method according to claim 8 wherein said water soluble contrast agent is metrizamide.
Claim 11
Dependent Claim
18 words
The method according to claim 1 wherein said composition is delivered into the periurethral tissue via a cystoscope.
Claim 12
Independent Claim
125 words
A method for the delivery of a composition comprising a biocompatible polymer, a biocompatible solvent, and a water insoluble contrast agent to the periurethral tissue of the mammal which tissue already has deposited therein with an initial amount of this composition which method comprises visualizing the position of the deposited composition in the periurethral tissue delivering a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent to the periurethral tissue of the mammal containing said deposited composition wherein said biocompatible polymer has an equilibrium water content of less than about 15% water and further wherein said delivery is conducted under conditions such that additional coherent polymeric mass forms in situ in the periurethral tissue thereby further reducing urinary incontinence in the mammal.
Claim 13
Independent Claim
125 words
A method for the delivery of a composition comprising a biocompatible polymer, a biocompatible solvent, and a water insoluble contrast agent to the periurethral tissue of the mammal which tissue already has deposited therein with an initial amount of this composition which method comprises visualizing the position of the deposited composition in the periurethral tissue delivering a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent to the periurethral tissue of the mammal containing said deposited composition wherein said biocompatible polymer has an equilibrium water content of less than about 15% water and further wherein said delivery is conducted under conditions such that additional coherent polymeric mass forms in situ in the periurethral tissue thereby further reducing urinary incontinence in the mammal.
Claim 14
Dependent Claim
16 words
The method according to claim 11 wherein visualization is conducted by direct visualization, fluoroscopy or ultrasound.
Claim 15
Independent Claim
74 words
A method for treating urinary incontinence in a mammal, which method comprises delivering a composition comprising a biocompatible polymer and a biocompatible solvent to the periurethral tissue of the mammal wherein said biocompatible polymer has an equilibrium water content of less than about 15% water and further wherein said delivery is conducted under conditions such that a coherent polymeric mass forms in situ in the periurethral tissue thereby reducing urinary incontinence in the mammal.
Claim 16
Independent Claim
74 words
A method for treating urinary incontinence in a mammal, which method comprises delivering a composition comprising a biocompatible polymer and a biocompatible solvent to the periurethral tissue of the mammal wherein said biocompatible polymer has an equilibrium water content of less than about 15% water and further wherein said delivery is conducted under conditions such that a coherent polymeric mass forms in situ in the periurethral tissue thereby reducing urinary incontinence in the mammal.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-07-27 | 2002-01-26 | 2002-07-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-07-27 | 2006-01-26 | 2006-07-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-07-27 | 2010-01-26 | 2010-07-28 | $7700.00 | Window Closed / Lapsed |